RYTHMOIRESEARCH
SMS Research Updates ↗

HCA / Healthcare

HCA Healthcare, Inc.

Services-General Medical & Surgical Hospitals, NEC

Company overview

HCA Healthcare, Inc. is an SEC-reporting issuer listed on NYSE under HCA. Its SEC industry description is Services-General Medical & Surgical Hospitals, NEC. This profile organizes annual financial disclosures for research; sector labels are editorial groupings, not GICS classifications.

Drug developers, device manufacturers and care providers depend on distinct clinical, reimbursement and operating economics.

Business segments

Segment-level revenue is not included in this standardized dataset. Consult the business and segment notes in the linked annual filing for the issuer’s actual reporting segments.

Selected fundamentals

Annual reporting currency: USD. Financial amounts are in millions, except per-share figures and ratios.

Latest period 2025-12-31 · prior period 2024-12-31
Metric2025-12-312024-12-31Source filed
RevenueUSD 75,600mUSD 70,603m2026-02-10
Operating incomeNot availableNot available2026-02-10
Net incomeUSD 6,784mUSD 5,760m2026-02-10
Diluted EPSUSD 28.33USD 22.002026-02-10
Operating cash flowUSD 12,636mUSD 10,514m2026-02-10
Capital expenditureUSD 4,944mUSD 4,875m2026-02-10
Free cash flowUSD 7,692mUSD 5,639m2026-02-10
Gross marginNot availableNot available2026-02-10
Operating marginNot availableNot available2026-02-10

FCF = operating cash flow − purchases of property, plant and equipment. Missing tags remain unavailable. Standardized cash-flow comparisons are particularly limited for financial businesses.

Inspect original metric provenance
{
  "revenue": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 75600000000,
    "accn": "0001193125-26-044769",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-10",
    "frame": "CY2025",
    "tag": "us-gaap:Revenues",
    "unit": "USD"
  },
  "netIncome": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 6784000000,
    "accn": "0001193125-26-044769",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-10",
    "frame": "CY2025",
    "tag": "us-gaap:NetIncomeLoss",
    "unit": "USD"
  },
  "eps": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 28.33,
    "accn": "0001193125-26-044769",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-10",
    "frame": "CY2025",
    "tag": "us-gaap:EarningsPerShareDiluted",
    "unit": "USD/shares"
  },
  "operatingCashFlow": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 12636000000,
    "accn": "0001193125-26-044769",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-10",
    "frame": "CY2025",
    "tag": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
    "unit": "USD"
  },
  "capex": {
    "start": "2025-01-01",
    "end": "2025-12-31",
    "val": 4944000000,
    "accn": "0001193125-26-044769",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-10",
    "frame": "CY2025",
    "tag": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment",
    "unit": "USD"
  },
  "totalAssets": {
    "end": "2025-12-31",
    "val": 60720000000,
    "accn": "0001193125-26-044769",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-10",
    "tag": "us-gaap:Assets",
    "unit": "USD"
  },
  "shareholdersEquity": {
    "end": "2025-12-31",
    "val": -6027000000,
    "accn": "0001193125-26-044769",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-10",
    "tag": "us-gaap:StockholdersEquity",
    "unit": "USD"
  },
  "currentAssets": {
    "end": "2025-12-31",
    "val": 15783000000,
    "accn": "0001193125-26-044769",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-10",
    "tag": "us-gaap:AssetsCurrent",
    "unit": "USD"
  },
  "currentLiabilities": {
    "end": "2025-12-31",
    "val": 16350000000,
    "accn": "0001193125-26-044769",
    "fy": 2025,
    "fp": "FY",
    "form": "10-K",
    "filed": "2026-02-10",
    "tag": "us-gaap:LiabilitiesCurrent",
    "unit": "USD"
  }
}

Annual earnings trend

Reported fiscal periods, not a live price chart.

Interactive chart loads in the browser. The full annual values are available below.

View all annual figures in a table
Period endRevenueNet incomeEPS
2025-12-31USD 75,600mUSD 6,784mUSD 28.33
2024-12-31USD 70,603mUSD 5,760mUSD 22.00
2023-12-31USD 64,968mUSD 5,242mUSD 18.97
2022-12-31USD 60,233mUSD 5,643mUSD 19.15

Valuation context

This release does not quote price-based multiples because it does not include synchronized market prices. A financial denominator must be paired with a clearly dated market value.

MeasureInterpretation
P/EPrice divided by EPS; identify annual, trailing or forward basis.
P/S & P/BMarket capitalization divided by sales or book equity.
EV / EBITDAEnterprise value and EBITDA need consistent definitions.
FCF yieldFree cash flow divided by dated market capitalization.

A sector median is descriptive, not a fair-value estimate. Explore sector context ↗

Selected filing notes

No filing note selected for this company in this release. Annual source filings remain available below.

Related research

Risks & what to monitor

Patent expiry, trial outcomes, reimbursement changes, litigation and acquisition integration.

Product concentration, research investment, utilization, reimbursement and cash generation.

Sources & dates